Renaissance Technologies
SBFM

Renaissance Technologies’s Sunshine Biopharma SBFM Stock Holding History

Renaissance Technologies’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,570
Closed -$83K – 3689
2025
Q3 		$83K Buy
5,570
+161
+3% +$2.39K ﹤0.01% 3276
2025
Q2 		$77.9K Buy
+5,409
New +$79K ﹤0.01% 3336
2024
Q2 		– Sell
-231
Closed -$279K – 3901
2024
Q1 		$279K Buy
231
+228
+7,600% +$670K ﹤0.01% 3116
2023
Q4 		$18K Buy
+3
New +$17.1K ﹤0.01% 3590

Other funds holding SBFM

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $3.05B AUM 18.61% 1-Year Est. Return

Renaissance Technologies's SBFM Position: Q4 2025 in Review

Renaissance Technologies sold out of Sunshine Biopharma (SBFM) in Q4 2025, closing a stake of 5,570 shares — an estimated $83K sold.

Renaissance Technologies first reported a position in SBFM in Q4 2023 and held it in 4 quarters. The position peaked at $279K in Q1 2024. 9 funds tracked by Wall St. Rank hold SBFM as of Q4 2025.

  • Renaissance Technologies reported no remaining Sunshine Biopharma position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 5,570 Sunshine Biopharma shares in Q4 2025, an estimated $83K.
  • Renaissance Technologies first reported a position in Sunshine Biopharma in Q4 2023 and held it in 4 quarters.
  • Renaissance Technologies's Sunshine Biopharma position peaked at $279K in Q1 2024.
  • 9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.